Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT02243891
Other study ID # LAAPITUP3
Secondary ID
Status Not yet recruiting
Phase Phase 4
First received September 16, 2014
Last updated March 8, 2015
Start date May 2015
Est. completion date October 2017

Study information

Verified date March 2015
Source Eastbourne General Hospital
Contact Ragunath Shunmugam, M.B,B.S
Phone +441323417400
Email r.shunmugam@nhs.net
Is FDA regulated No
Health authority United Kingdom: National Health Service
Study type Interventional

Clinical Trial Summary

The study will test the hypothesis that ablation of paroxysmal atrial fibrillation in hypertensive subjects is more effective when a ROX coupler is inserted concurrently.


Description:

The single blinded, randomised study is planned to commence in October 2014 after obtaining Research Ethics Committee and NHS Research and Development approval. A target of 20 participants with symptomatic paroxysmal AF will be recruited. All participants will be blinded and randomised to AF ablation only or AF ablation + ROX coupler implant. All participants will have right and left heart catheterisation prior to AF ablation +/- ROX coupler insertion. Participants will be followed up 6 weeks, 3, 6 months and 12 months after the ablation. The study will take place at Eastbourne District General. The study duration per patient is 13months. The overall study duration will be 18 months.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 40
Est. completion date October 2017
Est. primary completion date December 2016
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- Symptomatic paroxysmal AF suitable for AF ablation.

- Office Systolic blood pressure = 140 mmHg based on an average of 3 blood pressure readings

- Ambulatory Blood Pressure Monitoring (ABPM) daytime average systolic blood pressure (SBP) = 135 mmHg;

- Resistant Hypertension: Patients with established hypertension (diagnosed = 12 months prior to baseline) and is on a guideline based drug regimen at a stable and a fully tolerated dose, consisting of =3 hypertensive medications (including 1 diuretic), or

- Uncontrolled Hypertension: Patient has drug intolerances to antihypertensive medications and is unable to take a guideline based drug regimen

- VO2 peak > 15mls/Kg/min on Cardiopulmonary exercise testing (CPX)

- Peak RER > 1.0 on Cardiopulmonary exercise testing

- Age over 18 years old.

- Informed consent to participate in this study.

Exclusion Criteria:

- Secondary hypertension amenable to conventional therapy

- Left ventricular systolic dysfunction with EF < 50%

- E/E' > 15 on transthoracic echocardiography

- Uncontrolled diabetes.

- Body Mass Index > 40 kg/m2

- Contraindicated for treatment with an arteriovenous anastomosis or interventional vascular procedure

- Severe chronic kidney disease as indicated by estimated glomerular filtration rate < 30 mL/min/1.73m2 using the MDRD calculation

- Renal denervation within the last 6 months

- Significant peripheral arterial and/or venous disease in the lower limbs (including unprovoked deep vein thrombosis, significant lower extremity edema and/or venous insufficiency)

- Current diagnosis of unstable cardiac disease requiring intervention,or significant history of serious cardiac comorbidity that may affect patient safety or study outcomes

- Current diagnosis of severe cerebrovascular disease or stroke within the past year

- Female patient who is pregnant, breastfeeding or planning to become pregnant; females of child-bearing potential must have a negative urine pregnancy test prior to treatment

- Any known, unresolved history of drug use or alcohol dependency, lacks the ability to comprehend or follow instructions, or would be unlikely or unable to comply with study follow-up requirements

- Scheduled or planned surgery in the next 6 months that may affect patient safety or study outcomes

- Concurrent enrollment in another clinical trial without prior approval of ROX Medical, Inc.

- Any serious medical condition that may adversely affect the patient's safety, limit the subject's ability to participate in the study, comply with follow-up requirements or impact the scientific integrity of the study

- Intolerant or allergic to all anti-thrombolytic medications including aspirin

- Pulmonary arterial hypertension (PAH) defined as mean pulmonary artery pressure (mPAP) >30 mmHg as measured by right heart catheterization

- Pulmonary capillary wedge pressure (PCWP) > 15mmHg as measured by right heart catheterization

- Pre-existing ILRs or permanent pacemakers that do not allow for continuous monitoring for AF occurrence.

- Participation in a conflicting study.

- Potential participants who are mentally incapacitated and cannot consent or comply with follow-up.

- Pregnancy.

- Other cardiac rhythm disorders.

- Severe aortic and mitral valve disease.

- Previous ROX coupler implantation.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Procedure:
Atrial fibrillation ablation
Percutaneous catheter ablation for Atrial fibrillation.
ROX Coupler insertion
The ROX Coupler is a CE-marked device designed to maintain an iliac arteriovenous fistula

Locations

Country Name City State
United Kingdom Eastbourne District General Hospital Eastbourne East Sussex

Sponsors (1)

Lead Sponsor Collaborator
Neil Sulke

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary AF ablation success No AF burden detected on implantable loop recorder 3 months No
See also
  Status Clinical Trial Phase
Terminated NCT04591808 - Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia Phase 3
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Completed NCT03093532 - A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT05529147 - The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Recruiting NCT05976230 - Special Drug Use Surveillance of Entresto Tablets (Hypertension)
Completed NCT06008015 - A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers Phase 1
Completed NCT05387174 - Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period N/A
Completed NCT04082585 - Total Health Improvement Program Research Project
Recruiting NCT05121337 - Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension N/A
Withdrawn NCT04922424 - Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men Phase 1
Active, not recruiting NCT05062161 - Sleep Duration and Blood Pressure During Sleep N/A
Not yet recruiting NCT05038774 - Educational Intervention for Hypertension Management N/A
Completed NCT05087290 - LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
Completed NCT05621694 - Exploring Oxytocin Response to Meditative Movement N/A
Completed NCT05688917 - Green Coffee Effect on Metabolic Syndrome N/A
Recruiting NCT05575453 - OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure N/A